Showing 7271-7280 of 7715 results for "".
- CSF Unveils New Faculty, Sessions for 2014 Meetinghttps://practicaldermatology.com/news/20140724-csf_unveils_new_faculty_sessions/2459158/Cosmetic Surgery Forum has added new faculty members and educational sessions to its agenda. New to the podium this year will be Joel Cohen, MD, Ellen Marmur, MD, Gerald Goldberg, MD, Michael Greenberg, MD, Sabrina Fabi, MD, and Laurin Council, MD. New sessions include "Polishing Your Neurotoxin Tec
- Study: Dermatologists Preferred for Skin Cancer Evaluation and Treatmenthttps://practicaldermatology.com/news/20140722-study_dermatologists_preferred_for_skin_cancer_evaluation_and_treatment/2459161/Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey, respondents were asked their choice for evaluating a worrisome lesion on the face and for remov
- Viscot Offers New White Ink Markershttps://practicaldermatology.com/news/20140717-viscot_offers_new_white_ink_markers/2459165/Viscot Medical introduced White E•Z Removable Ink™to complement their existing green and red E•Z Removable Ink™ markers. E•Z Removable Ink™ comes off easily with an alcohol swab or water. E•Z Removable Ink™ eliminates the problem of patient
- LEO Pharma and KLOX Technologies Strike Global Dermatology Dealhttps://practicaldermatology.com/news/20140715-leo_pharma_and_klox_technologies_strike_global_dermatology_deal/2459167/LEO Pharma A/S and KLOX Technologies Inc. have entered into a worldwide license and joint venture agreement, excluding Canada, to further develop and commercialize KLOX's BioPhotonic technology platform in dermatology, which includes a CE-approved treatment for moderate to sever
- FDA Grants Orphan Drug Designation for Galderma's Trifarotene Molecule to Treat Congenital Ichthyosishttps://practicaldermatology.com/news/20140702-fda_grants_orphan_drug_designation_for_galdermas_trifarotene_molecule_to_treat_congenital_ichthyosis/2459180/The FDA granted orphan drug designation status for Galderma's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma says it pla
- Jan Marini Skin Research Marks 20 Years of Innovationhttps://practicaldermatology.com/news/20140625-jan_marini_skin_research_marks_20_years_of_innovation/2459188/After 20 years, Jan Marini Skin Research (JMSR) continues to distinguish itself as a recognized leader in the professional skincare industry through its combined focus on results, new productinnovation and its commitment to clinical and medical validation. Robert Weiss, MD, conducted a st
- FDA Issues Guidance Supporting the Responsible Development of Nanotechnology Productshttps://practicaldermatology.com/news/20140625-fda_issues_guidance_supporting_the_responsible_development_of_nanotechnology_products/2459190/Three final guidances and one draft guidance were issued by the U.S. Food and Drug Administration providing greater regulatory clarity for industry on the use of nanotechnology in FDA-regulated products. Nanotechnology is an emerging technology allowing scientists to create, explore, and
- Dermatologist Lynette J. Margesson, MD Recognized as NAPW Woman of the Yearhttps://practicaldermatology.com/news/20140624-dermatologist_lynette_j_margesson_md_recognized_as_napw_woman_of_the_year/2459193/The National Association of Professional Women (NAPW) honored Lynette J. Margesson, MD of Danby & Margesson Dermatologists, as a 2014 Professional Woman of the Year. Dr. Margesson is recognized with this prestigious distinction for leadership in medicine.
- South Beach Symposium Debuts New Host Hotelhttps://practicaldermatology.com/news/20140623-south_beach_symposium_debuts_new_host_hotel/2459198/The 13th annual meeting of the South Beach Symposium moves to the Fontainebleau Hotel in Miami Beach, February 12-16, 2015. Faculty for the event have been announced on the SBS website. There are non-overlapping CME tracks: the Mas
- Valeant Pharmaceuticals Receives FDA Clearance For Restylane Silkhttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_receives_fda_clearance_for_restylane_silk/2459205/The FDA issued marketing clearance for Valeant Pharmaceuticals International, Inc.'s Restylane Silk Injectable Gel with 0.3% Lidocaine for submucosal implantation for lip augmentation and dermal implantation for correction of perio